Chronische Hepatitis B

Schlüsselwörter

chronische Hepatitis B

Key words

chronic hepatitis B

Literatur

• 1 Alter M J. Epidemiology and prevention of hepatitis B.  Sem Liver. 2003;  23 39-46
• 2 Chang T T, Gish R G. et al . A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.  N Engl J Med. 2006;  354 1001-1010
• 3 Chen C J, Yang H I. et al . Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.  JAMA. 2006;  295 65-73
• 4 Colonno R J, Rose R, Baldick C J. et al . Entecavir resistance is rare in nucleoside naive patients with hepatitis B.  Hepatology. 2006;  44 1656-1665
• 5 Cornberg M, Protzer U, Dollinger M M. et al . [Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011].  Zschr Gastroenterol. 2007;  45 525-574
• 6 Erhardt A, Blondin D, Hauck K. et al . Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.  Gut. 2005;  54 1009-1013
• 7 Ganem D, Prince A M. Hepatitis B virus infection - natural history and clinical consequences.  N Engl J Med. 2004;  350 1118-1129
• 8 Hadziyannis S J, Papatheodoridis G V, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.  Hepatology. 2000;  32 847-851
• 9 Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.  Gastroenterology. 2006;  131 1743-1751
• 10 Hadziyannis S J, Tassopoulos N C, Heathcote E J. et al . Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.  N Engl J Med. 2003;  348 800-807
• 11 Hoofnagle J H, Doo E, Liang T J, Fleischer R, Lok A S. Management of hepatitis B.  Hepatology. 2007;  45 1056-1075
• 12 Iloeje U H, Yang H I, Su J. et al . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.  Gastroenterology. 2006;  130 678-686
• 13 Keam S J. Telbivudine.  Drugs. 2007;  67 1917-1929
• 14 Lai C L, Shouval D. et al . Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.  N Engl J Med. 2006;  354 1011-1020
• 15 Lau G K, Piratvisuth T, Luo K X. et al . Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.  N Engl J Med. 2005;  352 2682-2695
• 16 Lok A S, McMahon B J. Chronic hepatitis B.  Hepatology. 2007;  45 507-539
• 17 Marcellin P, Lau G K, Bonino F. et al . Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.  N Engl J Med. 2004;  351 1206-1217
• 18 Rapti I, Dimou E, Mitsoula P, Hadziyannis S J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.  Hepatology. 2007;  45 307-313
• 19 Sherman M, Yurdaydin C, Sollano J. et al . Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.  Gastroenterology. 2006;  130 2039-2049
• 20 Thimme R, Blum H E. Therapie der Hepatitis B.  Schweizerische Rundschau für Medizin Praxis. 2006;  95 1383-1388
• 21 Thimme R, Spangenberg H C, Blum H E. Hepatologie 2007.  Dtsch Med Wschr. 2007;  132 1392-1395